Democracy Spraffa

12 - MAT Standards

North Ayrshire Council · 25 August 2022
Back to Integration Joint Board — 25 August 2022 and its agenda

Text extracted from the council's PDF. Layout and reading order may differ from the original.

Original council PDF · Download plain text

Some pages contain no extractable text. They may be blank, graphics or scanned pages. OCR has not been applied.

Page 1

Integration Joint Board 
25th August 2022
Subject : North Ayrshire HSCP & ADP
Implementing Medication Assisted Treatment -
Annual Report 
Purpose : To present information on the implementation of new Medication
Assisted Treatment (MAT) Standards and for the IJB to be aware
of the next steps in delivering MAT and the obligations required
from Chief Officers and Chief Executives  
Recommendation : IJB are asked to note the content of the accompanying report
IJB are also asked to note and act on the obligations contained
within recent correspondence from the Minister for Drugs Policy
which details specific governance and accountability
responsibilities for Chief Officers and Chief Executives 
Direction Required to
Council, Health Board or
Both 
Direction to :- 
1. No Direction Required X
2. North Ayrshire Council 
3. NHS Ayrshire & Arran 
4. North Ayrshire Council and NHS Ayrshire & Arran 
Glossary of Terms 
IJB Integrated Joint Board
HSCP Health and Social Care Partnership
ADP Alcohol and Drug Partnership
MAT Medication Assisted Treatment
DRD Drug Related Death
MIST MAT Implementation Support Team 
1. EXECUTIVE SUMMARY 
1.1 To present a report North Ayrshire HSCP and ADP on the implementation of new MAT
Standards for management and assurance purposes and to provide information on
the requirement of a new North Ayrshire MAT Improvement Plan which is to be
personally signed off by the end of September by Chief Officers and Chief Executives

Page 2

2. BACKGROUND 
2.1 The MAT standards are one of the platforms for successful delivery of the National
Mission to save and improve lives in response to Scotland’s drug deaths crisis. The
standards enshrine a rights-based approach to immediate, person-centred treatment
for problem drug use, linked to primary care, mental health and other support services.
OVER SERVICE (NAD 
The accompanying report (Appendix 1 - ‘MAT annual summary report’) provides
information from April 2021 to March 2022 on the implementation and progress on
initiating MAT delivery in North Ayrshire. 
Appendix 2 provides detail of the RAG status for each of MAT Standards 1-5 for
each ADP area.    NHS Ayrshire and Arran are well placed in terms of progress. 
3. PROPOSALS 
IJB are asked to note the information included in the accompanying report in relation
to:
• The processes involved in the introduction of MAT delivery;
• The Test of Change process and the positive impact of this
• The improvement in access times to commencing treatment that supports an
individual’s recovery;
• Data on MAT delivery;
• Client experience and case studies
• Staff experience 
The IJB are also asked to note the information contained in (Appendix 3 - North
Ayrshire Assessment of progress by MIST July 2022.  The report provides an overview
of the MIST’s assessment of MAT implementation in North Ayrshire and also provides
a number of Improvement Actions to be included in a new North Ayrshire MAT
Improvement Plan. 
In addition, the IJB are asked to note the obligations contained within recent
correspondence from the Minister for Drugs Policy (Appendix 4) – namely: 
‘Ministers will expect the following actions to be taken and oversight arrangements in
place in each local area: 
a) That, by the end of September, Chief Officers and Chief Executives personally sign
timed, specific and published Improvement Plans for implementing the standards – to
include the delivery recommendations being made locally with MIST which are to be
published by PHS on 2 August; 
b) The Improvement Plans and the reporting on progress must involve and include the
voices of those with lived and living experience. It will be for each local area to
determine what arrangements it needs to have in place to ensure this is done,

Page 3

potentially drawing on MIST lived experience support, from third sector partners or from
their own local forums or panels; 
c) That Chief Officers and Chief Executives take shared and visible responsibility for
delivering the standards (with the Chief Officer being responsible for overall delivery and
the Chief Executives committing to support them). This requirement should align with
on-going work to define and refine local governance and accountability over alcohol and
drug services; 
d) That Chief Officers and Chief Executives include reports on progress as part of the
regular Board quarterly reporting against Annual Delivery Plans (the first report in this
series is due in July 2022); 
e) Health Boards, Integration Authorities and local authorities are to identify a senior
leader for each Integration Authority area as the single point of operational responsibility
for driving the changes necessary; 
f) Should any quarterly report identify the need for intervention, that this is acted on
immediately ‘. 
3.2 Anticipated Outcomes 
The implementation of the MAT Standards is part of a wider range of interventions
with the desired outcome of preventing Drug Related Deaths (DRD) and offering
more timely and appropriate treatment to support an individual’s recovery.   
3.3 Measuring Impact 
These Standards are now part of a continuous implementation, review, monitoring
and improvement cycle delivered by local services whilst being supported by the
national MAT Implementation Support Team (MIST) in line with Scottish
Government priories in relation to the prevention of DRD’s. 
The agreed Improvement Plan will guide services to ensure that MAT standards 1 to
5 are fully implemented by April 2023 and that Standards 6 to 10 are, at least,
partially embedded by April 2023 
4. IMPLICATIONS 
4.1 Financial
Additional funding to support the initial implementation of MAT delivery has been
sought and approved from both the ADP and the Scottish Government (however, this
funding was only confirmed in July 2022). 
4.2 Human Resources
A wide range of staff from across the HSCP, ADP and partner services are involved
in the delivery and evaluation of these MAT Standards.

Page 4

4.3 Legal
Detailed within the correspondence from the Minister for Drugs Policy, although not
detailing a legal require, there is reference to a clear expectation that actions will be
taken and oversight arrangements are put in place in local area. 
4.4 Equality/Socio-Economic
The full implementation of the MAT Standards will have a direct positive impact on
some of the most vulnerable members of society. 
4.5 Risk
Staff recruitment continues to be an issue and the availability of premises in locality
areas to undertake the full range of MAT interventions. 
4.6 Community Wealth Building
N/A 
4.7 Key Priorities
The implementation of these Standards is a key Scottish Government priority to
support the delivery of local strategic and operational plans across statutory and
partner services and support wider actions to prevent Drug Related Deaths in line with
the National Mission 
5. CONSULTATION 
Staff and service users from across various services have contributed to the
production of this report. 
Director – Caroline Cameron
For more information please contact Thelma Bowers, Head of Mental Health  on
[01294 317763 or thelmabowers@north-ayrshire.gov.uk] 
Appendices
• Appendix 1 - MAT annual summary report
• Appendix 2 – Implementation Status – National Picture
• Appendix 3 - North Ayrshire Assessment of progress by MIST July 2022’
• Appendix 4 - Correspondence from the Minister for Drugs Policy - MAT

Page 5

Aim:  To have no barriers to accessing treatment and care
that supports an individual’s recovery. This project focussed
specifically on improving access to appropriate Medication
Assisted Treatment (MAT) in order to prevent deaths, reduce
harms and promote recovery opportunities.
IMPLEMENTING MEDICATION ASSISTED
TREATMENT (MAT)   
NORTH AYRSHIRE DRUG AND ALCOHOL RECOVERY SERVICE (NADARS)
Reporting period:  1st April 2021 - 31st March 2022
Quality issue:  The numbers of drug related deaths in Scotland continue to increase. In 2020, there were 1,339 drug related
deaths, which is the largest number ever recorded and an increase on the previous year. Ayrshire and Arran have the second
highest death rate per 100,000 population. Evidence suggests quick access to treatment is crucial and being in treatment can be a
protective factor for majority of individuals.   The Scottish Drug Deaths Taskforce (SDDTF) has prioritised the introduction of the
MAT standards to help reduce the number of drug related deaths. There is evidence that rapid access to MAT meets the needs of
highly vulnerable groups and reduces mortality.
Measurement of improvement
Tests of change
Effects of change:
Cycle 1:  Implement and Test the MAT clinic pathway on a
Monday and a Thursday in one locality (Three Towns).
Cycle 2:  Secure funding to recruit staff to support the
implementation of the full model.
Cycle 3:  Refine project charter to facilitate full model
(in progress and now upscaling towards full model)
Cycle 4:  Expand service to 5 days per week across all of
North Ayrshire.
Improvement in the waiting time from point of referral to
commencement of appropriate Opiate Substitution Therapy
medication - average time from assessment to prescribed
medication reduced from 21 days to 1 day (from pilot period
to current date).
Improvement in satisfaction and experience of clients.
All individuals received a mental health assessment and
support as required.
All individuals were offered Blood Borne Virus (BBV) testing,
Harm Reduction interventions, physical health assessment
and referred on for further support where required.
All individuals had the opportunity to access Recovery
Development Worker's with lived experience to provide
person centred recovery support.
All individuals had the opportunity of family involvement.
All individuals were offered housing, advocacy support and
were referred for social care support where appropriate.
There were no unplanned discharges within the reporting
period.

Page 6

0 5 10 15 20 25
0-24
35-44
55+
IMPLEMENTING MEDICATION ASSISTED TREATMENT
(MAT)  
NORTH AYRSHIRE DRUG AND ALCOHOL RECOVERY SERVICE (NADARS)
Annual summary:  1st April 2021 - 31st March 2022
REFERRALS BY GENDER REFERRALS BY GENDER AND AGE GROUP
COMMENCED MAT SAME DAY/NEXT DAY
(where clinically appropriate and safe)
FEMALES MALES
41
43%
55
57%
79%
OPIOID SUBSTITUTION MEDICATIONS PRESCRIBED
FOLLOWING ASSESSMENT
ESPRANOR METHADONE
19 61
78%
NALOXONE AND OVERDOSE AWARENESS
Of clients were
supplied with
Naloxone
**The remaining 22% declined or
already had a kit **
INTERVENTIONS OFFERED AT POINT OF
MAT DELIVERY
Of clients were offered Mental
Health Support and harm
reduction interventions
including BBV testing, IEP and
Sexual Health
100%
CLIENT EXPERIENCE 
INDIVIDUALS IDENTIFIED AS HIGHER RISK *
10%
Of clients were identified as at
higher risk at point of assessment
(and received additional support)
*as defined by the MIST/MAT reporting criteria*
Of clients commenced MAT
on same day or next day
from assessment
100%
Of clients were
offered Naloxone
**  individuals were given a short term methadone prescription
to stabilise before being transferred to Espranor**
client changed their mind
client went to prison
not ready to commence MAT but continued to
receive support from the wider service.
96 clients chose this pathway of support.  Following
assessment 80 agreed to commence. 
Reasons for not commencing the pathway were:
100%
100%
of clients felt that they were
given sufficient information to
make an informed choice on
their treatment options
100%
of clients who were able to
commence their medication at
their initial appointment stated
that there were no delays in
getting their prescription
100%
of clients felt that the NADARS
worker explained all the care
and treatment options in a way
that they understood
100%
of clients rated the overall
service "excellent" or "very
good"
100%
of clients rated their initial
assessment either "excellent"
or "very good"
of clients rated the
communication from NADARS
either "excellent" or "very good

Page 7

CASE STUDIES
Case study 1
Case study 2
A 38 year old female was referred to NADARS in October and assessed via the MAT pathway. The client wished to
be commenced on OST to allow her to gain stability from illicit heroin use. The client was commenced on
Espranor.  Since being commenced on OST, the client has had two significant lapses, however, with support from
her key worker, has been able to identify triggers and worked on functional alternatives to drug use, to enable
stability and reduce the risk of further lapses in the future.  The client has now been abstinent from all illicit
substances since December 2021. She has been able to recognise the marked improvement in her mental health
since becoming abstinent and is using this as motivation to continue.  The client is now attending many different
community recovery groups and is linked in with the Recovery Development Workers for extra support. In the
long term, the client is hopeful that by maintaining stability, this will allow her to have more contact with her child.
Service information
Client referred into NADARS 27/05/2021. Assessed on 31/05/2021 and ORT prescription was commenced on
01/06/2021. Client was seen at least weekly and had regular telephone support in between face to face
appointments.  Client was offered interventions from NADARS Health Addiction Nurses for specialist input and
BBV testing.  Client was transferred from MAT Clinic into regular locality for allocation of new keyworker.
Client Feedback
It was really fast getting put onto a prescription at first which was so much better than having to wait for weeks. I
got lots of support with my workers and appointments. It made things easier to reduce my heroin use. I did well
for first few weeks but started injecting again and taking other drugs around 2 months into treatment. I was
linked in with the peers and this helped by going to meetings and having regular keyworker support. I have now
been stable on my prescription for a long time and I feel in control of my recovery. My worker is supportive and
my dispensing has been reduced and this helps me with my mobility. I am in a new relationship now and my
partner is supportive of my recovery. I no longer attend the group meetings but I have rebuilt my relationships
with my family and I want to continue to remain stable and look at reductions to my prescribed medication in the
next few weeks.
Case study 3
23 year old female referred by NADARS social care addictions worker on 28/09/21 and appointment accepted
via NADARS MAT (Medication Assisted Treatment) clinic on 30/09/21, for rapid access to OST (Opiate
Substitution Therapy).  Client reported history of alcohol and illicit substance use including; heroin,
benzodiazepines, cocaine and pregabalin. Previously admitted to ward 5, Woodland View for inpatient detox in
April 2021; however, had taken early self-discharge. Not previously engaged with OST.   Client's goal to regain
abstinence from all substances and alcohol. Wishing to achieve this via OST, preference for espranor, and
engaging with support.
Client was assessed by the staff nurse and consultant psychiatrist as planned on 30/09/21. Reported to have
been snorting heroin sporadically over the last year and in recent months had increased to once or twice week.
However, over the last few weeks this had increased further to around 2 bags daily and change of route to
smoking. Also reported use of illicitly diverted prescription grade espranor, being used nasally. Further reported
significant but unspecified amounts of street tablet use, as well as crack cocaine use.  Current supports in place
via criminal justice, SHINE, Housing First and Money Matters. Significant offending behaviour and complex
mental health issues.
Client was commenced on a 5 day methadone prescription (30ml daily supervised) with plan for transition to
espranor medication.  Client then opted to remain on methadone prescription rather than transferring to
espranor.  Client engaged with MAT clinic appointments for a 6 week period prior to her care being transferred
to a key worker within the wider team. Client  is now abstinent from illicit substances and engaging with
supports.

Page 8

Staff buy in to complete systems and
follow processes . 
Systems require to be fit for purpose
for data recording. 
Buy in from staff. 
Good communication across the teams. 
Set guidance so all staff are aware of
the process.
Increased monitoring support for all
clients
Response:
Staff experience of MAT standards
of staff rated their current knowledge
and understanding of the MAT
standards as "excellent" or "very
good"
of staff felt supported to gain the
knowledge, skills and confidence
to implement the standards.
100%
100%
positive feedback was received
from clients on the new MAT
model
MAT is a vast improvement
with regards to waiting times to
be seen and receive prescribed
medication. 
I have only received positive
feedback from prescriber and
client on this new MAT model.
Response:
Question:  What is required in
order for the MAT standards to
be rolled out as a sustainable
and consistent model?
Question:  Please state any further
comments/suggested improvements
you would like to make on the delivery
of the MAT standards so far?
Feedback received from other clients
across North Ayrshire is that they
would be prepared to travel to Caley
Court if they could receive same day
MAT intervention, however other
clients would prefer to be seen in
their own locality areas.
Response:
Feedback was received from a small staff group, who were more specifically involved in
the MAT Test of Change.
Next steps - There is currently an implementation plan in place to ensure full
MAT delivery is extended across North Ayrshire by the end of the summer.

Page 9

No embedded text on this page.

Page 10

This table provides the detail of RAG status for each of MAT standards 1-5 for each
ADP area.

Page 11

Appendix 6: NHS Ayrshire & Arran, North Ayrshire 
ADP area
Evidence-based assessment of progress, MAT standards
1–5. April 2022
Overview of MAT service provision
The North Ayrshire Drug and Alcohol Recovery Service have developed pathways of
support so that there will be no barriers to accessing treatment and care that
supports an individual’s recovery. The focus is on improved access to appropriate
MAT in order to prevent deaths, reduce harms and promote recovery opportunities.
Harm-reduction interventions will be delivered alongside physical and mental, health-
related support to enable individuals to remain in treatment for as long as required.
Accompanying psychological and social support will be available to all individuals.
An improvement/action plan has been identified and agreed with the MIST and this
will be supported via the local North Ayrshire Drug and Alcohol Recovery Service
Clinical and Care Governance Group, a local multi-agency Oversight Group and a
pan-Ayrshire MAT Steering Group to ensure consistency of MAT delivery across
Ayrshire and Arran. The work of lived experience interviews and recommendations
will also form part of the local and pan-Ayrshire improvements
MAT standard 1 is partially implemented (amber)
There is process evidence to demonstrate a current test of change and an ongoing
service that enables people to receive a prescription for opioid substitution therapy
on the day of first presentation. This is currently being scaled up to be five days a
week but is not yet available in justice settings. There is a pan-Ayrshire and Arran
standard operating procedure that offers guidance and consistency across the three
council areas. This document outlines referral processes including the option of

Page 12

same day prescribing, choice of opioid substitution therapy, care plan review
processes, pathways to identify people at risk of drug harm, pathways for harm
reduction and recognition that the recovery care package should differ depending on
the individual's needs and requirements. 
Numerical data from October to December 2021 indicate:
• 50% (n=16) of people were prescribed on the day of referral
• 25% (n=8) of people waited two days or less. 
Numerical data taken from the pilot between January to March 2022 indicate: 
• 83% (n=15) of people where prescribed on the same day.
These figures most likely represent only a portion of a person's journey from first
presentation to the multi-agency team to a prescription. Clinical audit of a
documented pathway is required. 
Experiential evidence provided following the pilot to improve services in North
Ayrshire reported that the 32 people who commenced medication assisted treatment
on same day, or the next day after assessment, received a mental health
assessment and support as required, and had the opportunity of family involvement.
All people had the opportunity to access recovery development workers with lived
experience to provide person centred recovery support. 
This standard is partially implemented (amber) because at this time, evidence does
not indicate consistent access across the ADP. While data imply that to rapid access
is available, this is only the data from the pilot. There are documented plans in place
to scale up and offer same day prescribing across the geographical area, that will
progress to full implementation of the standard. 
MAT standard 2 is fully implemented (green)
Process evidence indicates that clinical guidelines include methadone, short, and 
long-acting buprenorphine as treatment choices for people who present to services.
These are also available in local formularies. A Home Office licence is in place to

Page 13

allow for the storage and supply of opioid substitution therapies from the Caley Court
Resource Centre There is pan-Ayrshire standard operating procedure for named
patient prescribing for 
long-acting injectable buprenorphine medication to offer choice across a wider
geographical area. For people accessing services, information leaflets are available
to inform and support the choice of opioid substitution therapy. 
Numerical evidence provided from October to December 2021 indicates that the
proportion of people prescribed specific medication was as follows:
• methadone 87% (n= 714)
• oral buprenorphine 12% (n=97) 
• long-acting injectable buprenorphine 1% (n=8). 
January to March 2022 the figures remained stable. 
The ADP reports the uptake for long-acting buprenorphine has been slow but is a
treatment choice for all people across the ADP area. 
This standard is fully implemented (green) as all process documentation is in place
to allow people across the ADP area to have a choice of MAT. 
MAT standard 3 is fully implemented (green)
There is a pan-Ayrshire Near-fatal Overdose Emergency Response Pathway
outlining the approach to safely respond to people experiencing near-fatal overdoses
who have been identified by the Scottish Ambulance Service. The MAT standard
operating procedure guides staff to conduct a formal risk assessment to identify
people who are particularly vulnerable when accessing the service. This includes,
but is not limited to, people identified at higher risk, and people leaving prison. A
more detailed Prison Addiction Service standard operating procedure also supports
this and further work is in progress to ensure MAT Standards are embedded in these
settings by 2022.

Page 14

Information sharing agreements are in place between NHS Ayrshire and Arran,
Scottish Ambulance Service, Police Scotland, Scottish Fire and Rescue Service, and
the Health and Social Care Partnership. Guidance is available for staff to support
individuals experiencing co-existing mental health, alcohol and/or drug use. This
includes notification and referral processes to alert services if an immediate
response is required. Adult and child protection procedures are in place. 
Numerical data from January to March 2022 indicate that there were 46 notified
incidents reported with all people receiving an initial assessment on the same day.
From October to December 2021, five incidents were notified and the median wait
was four days. All people received a joint community and substance use
intervention.
The ADP has documented plans to build upon the existing ‘Duty Triage Team’ to
create a wider North Ayrshire drug and alcohol recovery service response team
offering same day MAT assessments and prescribing (minimum of five days a
week). It will respond to near-fatal overdose, offer administration of long-acting
injectable buprenorphine, regular review appointments, support for individuals
released from prison and same day care for people in the Housing First programme.
This standard is fully implemented (green) because a documented system is in place
and there is good evidence that people receive an appropriate and timely response.
This model will be useful nationally. 
MAT standard 4 is fully implemented (green)
A MAT standard operating procedure defines a process for the delivery of harm-
reduction interventions for all staff across NHS Ayrshire and Arran. It states that all
staff are trained in overdose awareness and prevention and have access to
naloxone for personal-carry and onward supply. A harm-reduction checklist guides
and supports staff to discuss the three evidence-based harm-reduction interventions
(injecting equipment provision, take-home naloxone and blood-borne virus testing).

Page 15

Experiential evidence from the North Ayrshire Pilot indicates that all individuals in the
pilot were offered blood-borne virus testing, naloxone, injecting equipment, physical
health assessment including sexual health, and other harm-reduction interventions.
This standard is fully implemented (green) because the core harm-reduction
interventions, injection equipment provision, take-home naloxone and blood-borne
virus testing are reported to be available at the same time and place as all MAT
appointments in all community settings. This is evidenced by documentation. Justice
settings present a challenge and there needs to be a commitment to offer the full
range of harm-reduction interventions in all sites. 
MAT standard 5 is fully implemented (green)
The ADP reports a variety of approaches to enable retention in care and safe
discharge. There is a pan-Ayrshire Promotion Engagement in Addiction Services
standard operating procedure that is currently being reviewed and updated to reflect
MAT standard 5 and it recognises that the recovery care package should be specific
to the individual's needs and requirements. There is no option to prescribe opioid
substitute treatment in primary care services. Multi-disciplinary teams use
collaborative processes to support individuals accessing services. In turn, people are
supported to access primary care services such as GPs, community pharmacies,
opticians and dentists. Family or nominated persons are also encouraged to attend
to support retention of the service.
Numerical data provided indicate that:
• as of March 2022, 50% (n=457) of people had been on MAT for 1,839 days or
more (five years)
• between October to December 2021, of 67 planned discharges 50% (n=34)
were on MAT for 210 days or more 75% (n=50) for 55 days or more
• between October to December 2021, there were no unplanned discharges 
from MAT

Page 16

• between January 2022 to March 2022, the median time on MAT for unplanned
discharges was over 1,700 days and 75% (n=6) had received MAT for 16
months
or more.
This standard is fully implemented (green) as systems are in place to enable people
to stay in a treatment of their choice, for as long as they need. The service continues
to explore multiple forms of caseload management, including a tiered recovery
orientated model of care based on peoples own choice. The only limitation is no
shared care with primary care, however, pathways are in place to support
engagement with primary care. There is a process in place under standard 3 to
follow up people who disengage from treatment. Learning from this model could be
useful nationally. 
Progress with implementation of other projects
The implementation of MAT standards is not a stand-alone development and is
incorporated into other identified workstreams and projects, which include, but is not
limited to the following:
• Adherence to the new ‘Substance Use Treatment Target’.
• New responses and pathway of support for individuals following a 
near-fatal overdose.
• Improving the multi-agency pathways of support for individuals with a ‘Dual
Diagnosis’.
• Identification of pathways to support individuals to access residential 
rehabilitation support. 
• Enhanced support via the Housing First programme incorporating dedicated
alcohol and drug and mental health support.
• Dedicated advocacy worker.

Page 17

Improvement plan to implement the MAT standards by 
April 2023
The detailed action plan, Gantt chart and method for evaluation of change will be
developed by the ADP and MIST. A programme management approach will be taken
to complete the actions below. This will require committed resources to ensure
delivery. The ADP coordinator will sign off the programme.
1. Implement further test of change for MAT standards 2, 3 and 8 in
justice settings across Ayrshire and Arran and share learning
• Timeframe:
o Commence in August 2022 and report on the first quality improvement
cycle in December 2022, demonstrate partial or full implementation by
April 2023.
• Actions:
o Conduct mapping of the MAT standards in Ayrshire and Arran justice
settings and initiate systems to implement MAT standards across the
local pathways that link prison, police custody and the community.
o Ensure sufficient process, numerical and experiential evidence to 
demonstrate progress.
2. Scale up the MAT standards 1–10 in the community
• Timeframe:
o Commence in August 2022 and demonstrate full implementation of
standards 1–5 and at least partial implement of standard 6–10 by April
2023.
• Actions:

Page 18

o Collaborate with national thematic groups.
o Establish scale-up plans for all standards. Specific components for 
scale up include:
▪ Scale up the provision of accessible community based same day
prescribing across the whole of North Ayrshire (MAT standard 1).
▪ Scale up the provision of long-acting injectable buprenorphine to all
clients receiving MAT who wish it (MAT standard 2).
▪ Continue to develop models to retain people in services for as long
as they request by continued support of models of care creating
further capacity and share the learning nationally (MAT standard 5). 
▪ Provide structured psychological interventions (Tier 2) to address
mild to moderate comorbid mental health issues and to support
people's recovery from substance use. Enhance support and
training for psychologically informed treatment and trauma-informed
care (MAT standards 6 and 10).
▪ Continue to explore models of shared care with primary care (MAT
standard 7).
▪ Increase rights based advocacy support to people in treatment by
commissioning dedicated advocacy input (MAT standard 8).
▪ Continue to improve access to recovery groups and peer support.
▪ Continue to support access to family and carer support.
4. Assistance provided by the MAT Implementation Support Team
• Assist implementation of tests of change with examples and templates of
quality improvement charters, operating procedures, approaches to numerical
and experiential data collection (e.g. data sets, collection and analysis tools),
project cycle review, reporting and plans for scale up.

Page 19

• The establishment of thematic ADP clusters that will enable benchmarking,
information sharing, spread of good practice, development and dissemination
of tools (e.g. audits, template documents) and inter-organisational support.
• Implementation of a programme management approach to ensure 
systematic implementation.
• Updates of standard operating procedures, guidelines and plans in line with
the recommendations in the MAT standards and that address the gaps
identified through a review of the evidence provided.
• Capacity building and systems to collect numerical and experiential evidence
to demonstrate progress and use as part of the improvement cycles.

Page 20

Annex 1: Process evidence submitted
MAT standard Title Description
3 
Ayrshire and Arran
information sharing
protocol
Information Sharing
Protocol
1 Benzodiazepine
Prescribing Guideline
Prescribing Guidelines
1
Buprenorphine Oral
Lyophilisate Prescribing
within NHS Ayrshire and
Arran Community
Addictions Services
Prescribing Guidelines
1 & 2
Buvidal® (Buprenorphine
Depot) for Opioid
Substitution Treatment
Prescribing Guidelines
1 Care planning
presentation and training
Prescribing Guidelines
3
Child Protection
Wellbeing Concerns
Guideline (MHS)
Wellbeing Guidelines 
2
Choosing the right
treatment for opioid
dependence leaflet
Leaflet
4 Community Health
Addiction Nurse
Job Description 
3 G120 – Adult Support
and Protection Policy 
1
General principles of
prescribing practice
within NHS Ayrshire and
Arran addiction services
Prescribing Guidelines
3
Guidance for NADARS
staff requiring Mental
Health support
Guidance and flowchart

Page 21

MAT standard Title Description
3 
Guidance individuals with
co-existing mental health
and alcohol and or drug
issues
Guidance document
3 & 4
Harm-Reduction
Interventions with MAT –
Checklist
Checklist
5
Implementing medication
assisted treatment (MAT) –
client experience
Project poster +
Improvement plans
1 Index - material under
development
Index
1 MAT standards – planned
audit template
Audit
1
Medication Assisted
Treatment (MAT) Standard
Operating Procedure
Standard Operating
Procedure
3 NADARS – RAG
Recording (May 2021)
RAG recording guidance
1 NADARS and Ward 5 –
Service user satisfaction
Audit feedback
3 NADARS RAG status
RAG Status
1
NHS Ayrshire and Arran
complaints handling
procedure
Procedure (complaints)
3
Pan Ayrshire agreement
non-fatal overdose –
referral pathways and
processes
Procedure (NFOD)
5
Promoting Engagement
within Community
Addiction Services
Standard Operating
Procedure

Page 22

MAT standard Title Description
Standard Operating
Procedure
1
Record keeping for mental
health and learning
disability nurses and non-
registered professionals'
guideline
Record keeping standards
1 Suboxone flow chart
Flowchart
1
Supervision for Mental
Health, Learning Disability
nurses and non-registered
Professionals Guidance
Supervision guidance
1 The Ayrshire mental
health conversation
Strategic Plan
3
The Scottish Ambulance
Service (SAS) and the
North Ayrshire Drug and
Alcohol Recovery
Service (NADARS) non-
fatal overdose response
and support pathway
Service and referral
pathway 
Annex 2: Summary of numerical evidence provided
MAT standard 1 
Data source: Local database
Method, caveats and learning: Reports on individuals referred within the MAT pilot
area.
Results:

Page 23

Chart 1: Days from first contact to initiation of MAT in the MAT pilot
area 
Chart commentary: From October to December 2021, 31 people started MAT in the
MAT pilot area. From January to March 2022, 18 people started MAT. 50% (n=16) of
people were prescribed on the same day as referral with a further 25% (n=8) of
people waiting two days or less from referral to prescribing in October to December
2021. This number was reduced to zero days for 83% people (n=15) for the months
January to March 2022. The longest wait was 18 days in October to December 2021,
with the maximum waiting time in January to March 2022 being reduced to seven
days.
MAT standard 2
Data source: Local database
Methods, caveats and learning: People receiving a prescription including MAT
Pilot area.
Results:

Page 24

Chart 2: Number of people prescribed specific opioid substitution
therapy medications, October 2021 to March 2022. 
Chart commentary: From October to December 2021, the proportion of people
prescribed methadone was 87% (n= 714), oral buprenorphine accounted for 12%
(n=97) and injectable buprenorphine 1% (n=8). The total number of people
prescribed opioid substitution therapy was 819. In the period January to March 2022,
the proportion of people prescribed methadone decreased slightly to 86% (n= 703)
while the proportion of oral buprenorphine and injectable buprenorphine remained
the same. Comparing October to December 2021, the total number of people
prescribed opioid substitution therapy was 819, with this reducing to 814 over
January to March 2022.
MAT standard 3
Data source: Local database
Method, caveats and learning: Individuals referred through Near-Fatal Overdose
Pathway out with MAT Pilot area. The numbers for October to December 2021 are
low 
as recording started during that time. Numbers include existing people as well as
those newly identified.

Page 25

Results: From January to March 2022, all 46 notified high-risk incidents are reported
to have received an initial assessment on the same day. This is a reduction in time
when compared to October to December 2021, where fewer than five high-risk
incidents were notified and the median number of days wait was four, the longest
wait was seven days. All people assessed received a joint community and substance
use intervention.
MAT standard 4 
Data source: Local database
Method, caveats and learning: None stated.
Results: There is one location offering all three core harm reductions, take-home
naloxone and overdose, injecting equipment, and blood-borne virus testing, at initial
and subsequent appointments. This location also offers assessment of injecting risk,
wound assessment and sexual health counselling.
MAT standard 5 
Data source: Local database 
Method, caveats and learning: Individuals (including MAT Pilot area) who have
received a prescription during this reporting period and those who are no longer
receiving a prescription but still receiving support.
Following analysis of the data for planned and unplanned discharges at service level
(see chart 4 and 5 below), a range of explanations can be given to account for the
median being reduced.
Individuals accessing MAT may decide that, following assessment and prescribing,
that this is not the time for them to begin MAT. The North Ayrshire ADP will work with
North Ayrshire Drug and Alcohol Recovery Service to further understand how to
record this or what can be done to track individual's re-entry to the service. The
service is currently very proactive in following up, but these numbers may also
include those referred but never attended, and some individuals who appear to have

Page 26

moved address. There will be an ongoing element of these data that includes those
who may be placed on remand or have longer prison sentences.
These numbers will continually fluctuate (and are evident in previous data)
depending on patient choice, individuals' demographics and other social factors that
will continue to affect retention in treatment and discharge figures. The
understanding behind these circumstances and choices made can continue to be
explored further to inform 
service delivery.
Results:
• Part 1: Current MAT caseload. Refer to chart 3 below. 
• Part 2: Planned discharges. Refer to chart 4 below. 
• Part 3: Unplanned discharges. Refer to chart 5 below.
Chart 3: Number of people on the current caseload, December 2021
and March 2022 
Chart commentary: As at 31 December 2021, the number people on MAT on the
caseload was 830. This increased to 914 at the end of March 2022. Time currently

Page 27

on MAT ranged from 0 days to 4,434 (over 12 years) as at 31 December 2021,
compared to 0 days to 4,524 (over 12 years) by the end of March 2022. 50% (n=415)
of people had been on MAT for 1,897 days (over five years) or more as at 31
December 2021 compared to 31 March 2022 where 50% (n=457) of people had
been on MAT for 1,839 days (around five years) or more. 75% (n=623) currently
remained on MAT for 643 days (around 18 months) or more as at 31 December
2021 compared to 75% (n=686) remaining on MAT for 594 days (around 19 months)
or more at 31 March 2022.
Chart 4: Number of days retained on MAT for planned discharges,
December 2021 to March 2022 
Chart commentary: For the quarter ending 31s December 2021, there were 67
planned discharges from MAT. The minimum length of time on MAT was three days
and the maximum 4,249 days. 50% (n=34) of people discharged were on MAT for
210 days or more with 75% (n=50) of service users on MAT for 55 days or more. The
minimum and maximum number of days retained on MAT for planned discharges is
similar for the months of January 2022 to March 2022, however, the median number
of days decreased by 50%.

Page 28

Chart 5: Number of days retained on MAT for unplanned
discharges, January to March 2022 
Chart commentary: Between October and 31 December 2021 there were no
unplanned discharges from MAT. From January 2022 to March 2022, the median
time on MAT for unplanned discharges was over 1,700 days (approximately four and
a half years) and 75% (n=6) had received MAT for at least 470 days (approximately
16 months). 
Annex 3: Summary of experiential evidence provided
Data source Method and participants Comments 
Implementing MAT – Pilot
Report, North Ayrshire Drug
and Alcohol Recovery
Service (NADARS) 
Evaluation of pilot of
implementation of
medication assisted
treatment (MAT). 
Evaluation of outcomes of
pilot only (April–September
2021) so no data regarding
the longevity of support/
treatment or ‘moving on’.
NADARS and Ward 5 –
Service user satisfaction 
audit programme (2022)
Audit programme 2022:
plan for collecting service
user satisfaction.
Programme only – includes
plan to collect feedback
from people accessing
medication assisted
treatment.

Page 29

Scottish Ministers, special advisers and the Permanent Secretary are
covered by the terms of the Lobbying (Scotland) Act 2016.  See
www.lobbying.scot 
St Andrew’s House, Regent Road, Edinburgh  EH1 3DG
www.gov.scot

 
Minister for Drugs Policy
Angela Constance MSP 
T: 0300 244 4000
E: scottish.ministers@gov.scot

Integration Authority Chief Officers
Territorial Health Board Chief Executives
Local Authority Chief Executives 
Copied to:
Chairs of Territorial Health Boards and Integration
Joint Boards
COSLA
SOLACE
Alcohol and Drug Partnership Chairs
ADP leads 
«Address7» 
___
23 June 2022 
I am writing this letter of direction to all Territorial (Local) Health Boards, Integration
Authorities and local authorities, using authority from section 52 of the Public Bodies (Joint
Working) (Scotland) Act 2014 in relation to the carrying out of functions conferred by that
Act, delegated in pursuance of an integration scheme or to be specifically carried out in
conjunction with those, and which require specific responses to achieve implementation of
the Medication Assisted Treatment (MAT) standards published on 31 May 2021. 
The MAT standards are one of the platforms for successful delivery of the National Mission
to save and improve lives in response to Scotland’s drug deaths crisis. The standards
enshrine a rights-based approach to immediate, person-centred treatment for problem drug
use, linked to primary care, mental health and other support services.  Although the
standards were published on 31 May 2021, these had been well publicised and local areas
had contributed to their development through the Drug Deaths Taskforce. 
Both the First Minister and I announced that these standards needed to be embedded and
implemented by April 2022 and the Scottish Government is providing funding to help local
services deliver on embedding, improving and sustaining the MAT standards. We have also
established an implementation support team (MIST) including practitioners and people with
lived experience, and led by Public Health Scotland to support local areas scale up and
implement the standards. 
In 2021/22 we provided £6 million for MAT implementation along with £3 million for assertive
outreach and £3 million for non-fatal overdose pathways (both of those initiatives contribute
to MAT standard 3) as well as £4 million to support local areas for the use of long acting
buprenorphine (MAT standard 2).  We also provided £500,000 last year (and committed to
the same per year for the life of the Mission) for local areas to set up and run local forums or
panels to feed in views from people with lived and living experience to MAT implementation
as well as to other aspects of service delivery. I have also announced that funding for the
remaining years of the National Mission – to April 2026) has been increased from £6 million
to £10 million per year.

Page 30

Scottish Ministers, special advisers and the Permanent Secretary are
covered by the terms of the Lobbying (Scotland) Act 2016.  See
www.lobbying.scot 
St Andrew’s House, Regent Road, Edinburgh  EH1 3DG
www.gov.scot

 
Today, Public Health Scotland is publishing a MAT Implementation Benchmarking Report
which shows that while progress on implementation has been made in all areas, and MAT
standards 1 – 5 have been implemented fully in Borders, the standards had not been
implemented fully by April 2022. 
In response to this Report and in order to achieve full implementation, Ministers will expect
the following actions to be taken and oversight arrangements in place in each local area: 
a) That, by the end of September, Chief Officers and Chief Executives personally sign
timed, specific and published Improvement Plans for implementing the standards – to
include the delivery recommendations being made locally with MIST which are to be
published by PHS on 2 August; 
b) The Improvement Plans and the reporting on progress must involve and include the
voices of those with lived and living experience. It will be for each local area to
determine what arrangements it needs to have in place to ensure this is done,
potentially drawing on MIST lived experience support, from third sector partners or
from their own local forums or panels; 
c) That Chief Officers and Chief Executives take shared and visible responsibility for
delivering the standards (with the Chief Officer being responsible for overall delivery
and the Chief Executives committing to support them). This requirement should align
with on-going work to define and refine local governance and accountability over
alcohol and drug services; 
d) That Chief Officers and Chief Executives include reports on progress as part of the
regular Board quarterly reporting against Annual Delivery Plans (the first report in this
series is due in July 2022); 
e) Health Boards, Integration Authorities and local authorities are to identify a senior
leader for each Integration Authority area as the single point of operational
responsibility for driving the changes necessary; 
f) Should any quarterly report identify the need for intervention, that this is acted on
immediately. 
Further, I will follow up directly with any additional asks of Health Board or Integration
Authority areas where the proportion of drug deaths remains significantly high and where
MAT standard 1 is not yet implemented, and for those areas, we will require monthly
progress reports rather than quarterly. 
Our expectation is that, these oversight arrangements will lead to implementation of the MAT
standards in community and justice settings in all local areas, in accordance with the
timetable for full implementation being recommended in the PHS Benchmarking Report, at
the very latest. 
The Scottish Government and the MIST team, in particular, will continue to provide advice
and support to all local areas to set up the above arrangements and to achieve the intended
goals.  Addressing this requires a whole-system approach across Government and across
local services.

Page 31

Scottish Ministers, special advisers and the Permanent Secretary are
covered by the terms of the Lobbying (Scotland) Act 2016.  See
www.lobbying.scot 
St Andrew’s House, Regent Road, Edinburgh  EH1 3DG
www.gov.scot

 
The requirements set out in this letter of direction will subsequently be revoked when
implementation has been achieved locally, and notice of that will be in a further letter. 
I thank you, and those who are charged with delivering support and care in accordance with
the MAT standards, for your on-going commitment.  Ministers recognise that there are huge
efforts being made already to deliver on the standards and to provide the necessary care for
some of the most marginalised people in our communities, to save and improve lives.  This
letter is intended to ensure that the work being done on the ground is backed up more
consistently through commitment from senior leaders. 
ANGELA CONSTANCE